The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and semiconductors. The investigations are being conducted under Section 232 of the Trade Expansion Act of 1962, which authorizes the President to impose tariffs or other trade restrictions if an investigation determines that importation of particular goods affect national security. Those goods have received exemptions from tariffs on imported goods that began April 5. The agency will accept comments on domestic production, the role of foreign supply chains, the impacts of trade policy and other information related to pharmaceutical and semiconductor imports for 21 days following publication in the April 16 Federal Register. 

Related News Articles

Headline
The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released…
Headline
The AHA urged the Department of Commerce Oct. 17 to take a balanced approach to ensuring dependable and affordable access to personal protective equipment,…
Headline
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
The White House Sept. 5 issued an executive order modifying the scope of reciprocal tariffs announced in April to establish a framework of trade deals with…
Headline
The Department of Health and Human Services today announced prescription drug reforms that will become effective Oct. 1 originating from the Health Data,…